159 related articles for article (PubMed ID: 8527837)
1. Inhibitors of protein tyrosine kinases.
Fry DW; Bridges AJ
Curr Opin Biotechnol; 1995 Dec; 6(6):662-7. PubMed ID: 8527837
[TBL] [Abstract][Full Text] [Related]
2. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors.
Mohammadi M; McMahon G; Sun L; Tang C; Hirth P; Yeh BK; Hubbard SR; Schlessinger J
Science; 1997 May; 276(5314):955-60. PubMed ID: 9139660
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors.
Hinterding K; Knebel A; Herrlich P; Waldmann H
Bioorg Med Chem; 1998 Aug; 6(8):1153-62. PubMed ID: 9784857
[TBL] [Abstract][Full Text] [Related]
5. Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.
Schroeder MC; Hamby JM; Connolly CJ; Grohar PJ; Winters RT; Barvian MR; Moore CW; Boushelle SL; Crean SM; Kraker AJ; Driscoll DL; Vincent PW; Elliott WL; Lu GH; Batley BL; Dahring TK; Major TC; Panek RL; Doherty AM; Showalter HD
J Med Chem; 2001 Jun; 44(12):1915-26. PubMed ID: 11384237
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors.
Fry DW
Pharmacol Ther; 1999; 82(2-3):207-18. PubMed ID: 10454198
[TBL] [Abstract][Full Text] [Related]
7. Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases.
García-Echeverría C; Fabbro D
Mini Rev Med Chem; 2004 Mar; 4(3):273-83. PubMed ID: 15032674
[TBL] [Abstract][Full Text] [Related]
8. From oncogene to drug: development of small molecule tyrosine kinase inhibitors as anti-tumor and anti-angiogenic agents.
Morin MJ
Oncogene; 2000 Dec; 19(56):6574-83. PubMed ID: 11426642
[TBL] [Abstract][Full Text] [Related]
9. Topological designing of 4-piperazinylquinazolines as antagonists of PDGFR tyrosine kinase family.
Khadikar PV; Shrivastava A; Agrawal VK; Srivastava S
Bioorg Med Chem Lett; 2003 Sep; 13(18):3009-14. PubMed ID: 12941323
[TBL] [Abstract][Full Text] [Related]
10. Structural biology in drug design: selective protein kinase inhibitors.
Scapin G
Drug Discov Today; 2002 Jun; 7(11):601-11. PubMed ID: 12047871
[TBL] [Abstract][Full Text] [Related]
11. Rational design of 4,5-disubstituted-5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-ones as a novel class of inhibitors of epidermal growth factor receptor (EGF-R) and Her2(p185(erbB)) tyrosine kinases.
Sun L; Cui J; Liang C; Zhou Y; Nematalla A; Wang X; Chen H; Tang C; Wei J
Bioorg Med Chem Lett; 2002 Aug; 12(16):2153-7. PubMed ID: 12127526
[TBL] [Abstract][Full Text] [Related]
12. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor.
Fry DW; Bridges AJ; Denny WA; Doherty A; Greis KD; Hicks JL; Hook KE; Keller PR; Leopold WR; Loo JA; McNamara DJ; Nelson JM; Sherwood V; Smaill JB; Trumpp-Kallmeyer S; Dobrusin EM
Proc Natl Acad Sci U S A; 1998 Sep; 95(20):12022-7. PubMed ID: 9751783
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors in preclinical development.
Levitt ML; Koty PP
Invest New Drugs; 1999; 17(3):213-26. PubMed ID: 10665475
[TBL] [Abstract][Full Text] [Related]
14. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
Sun L; Tran N; Liang C; Tang F; Rice A; Schreck R; Waltz K; Shawver LK; McMahon G; Tang C
J Med Chem; 1999 Dec; 42(25):5120-30. PubMed ID: 10602697
[TBL] [Abstract][Full Text] [Related]
16. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: structure-activity relationships in quinoxalines, quinolines, and indole tyrphostins.
Gazit A; App H; McMahon G; Chen J; Levitzki A; Bohmer FD
J Med Chem; 1996 May; 39(11):2170-7. PubMed ID: 8667360
[TBL] [Abstract][Full Text] [Related]
17. Achieving selectivity between highly homologous tyrosine kinases: a novel selective erbB2 inhibitor.
Bhattacharya SK; Cox ED; Kath JC; Mathiowetz AM; Morris J; Moyer JD; Pustilnik LR; Rafidi K; Richter DT; Su C; Wessel MD
Biochem Biophys Res Commun; 2003 Jul; 307(2):267-73. PubMed ID: 12859950
[TBL] [Abstract][Full Text] [Related]
18. Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.
Mahboobi S; Teller S; Pongratz H; Hufsky H; Sellmer A; Botzki A; Uecker A; Beckers T; Baasner S; Schächtele C; Uberall F; Kassack MU; Dove S; Böhmer FD
J Med Chem; 2002 Feb; 45(5):1002-18. PubMed ID: 11855980
[TBL] [Abstract][Full Text] [Related]
19. Effect of herbimycin A on tyrosine kinase receptors and platelet derived growth factor (PDGF)-induced signal transduction.
Murakami Y; Fukazawa H; Mizuno S; Uehara Y
Biol Pharm Bull; 1998 Oct; 21(10):1030-5. PubMed ID: 9821805
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.
Boschelli DH; Wu Z; Klutchko SR; Showalter HD; Hamby JM; Lu GH; Major TC; Dahring TK; Batley B; Panek RL; Keiser J; Hartl BG; Kraker AJ; Klohs WD; Roberts BJ; Patmore S; Elliott WL; Steinkampf R; Bradford LA; Hallak H; Doherty AM
J Med Chem; 1998 Oct; 41(22):4365-77. PubMed ID: 9784112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
